Today on Rare Disease Day, we stand in solidarity with the millions of individuals living with rare diseases, including those affected by hypothalamic obesity and Prader-Willi syndrome. While these conditions are rare, the impact on patients and families is significant. By amplifying patient voices and fostering greater understanding, we can help drive meaningful change. Let’s continue to shine a light on rare diseases and work toward a future with better support and solutions for those affected. Rare Disease Day | #RareDiseaseDay #PraderWilliSyndrome #HypothalamicObesity
关于我们
Aardvark Therapeutics is a?clinical-stage biopharmaceutical company developing novel, small-molecule therapies designed to inhibit hunger and transform metabolic health
- 网站
-
https://aardvarktherapeutics.com/
Aardvark Therapeutics的外部链接
- 所属行业
- 制药业
- 规模
- 11-50 人
- 总部
- San Diego，California
- 类型
- 私人持股
- 创立
- 2017
地点
-
主要
获取路线
4370 La Jolla Village Dr
1050
US，California，San Diego，92121
Aardvark Therapeutics员工
-
Jeff Chi
Vice Chairman & Founding Partner at Vickers Venture Partners
-
Tien Lee
-
Justin Stege, Ph.D
Biotechnology Leader ? Program/Team Management ? R&D ? Collaborations
-
Ronald D. Lewis, II, Ph.D.
Technical & CMC Operations Lead | Non-Profit Board Member | Alzheimer’s and Dementia Patient & Caregiver Advocate | STEM Educator
动态
-
Dr. Tien Lee, Founder and CEO of Aardvark Therapeutics, joined Judy Shaw on?#NYSEFloorTalk?to talk about their innovative obesity drug, ARD-101. He shared how it stands out from other treatments, the encouraging data so far, and what their upcoming trials will focus on.
Dr. Tien Lee, Founder and CEO of Aardvark Therapeutics, joined Judy Khan Shaw on #NYSEFloorTalk to talk about their innovative obesity drug, ARD-101. He shared how it stands out from other treatments, the encouraging data so far, and what their upcoming trials will focus on.
-
Tien Lee, Founder and CEO of Aardvark Therapeutics, joins Nasdaq to celebrate our recent funding and discusses how our company specializes in gut brain interaction with a focus of inflammation and metabolism. #aardvarktherapeutics
Tien Lee, Founder and CEO of Aardvark Therapeutics, joins Nasdaq to celebrate their recent funding and discuss how the company specializes in gut brain interaction with a focus of inflammation and metabolism. Watch more: https://lnkd.in/eQK-Jv-N